CheckCap (CHEK)
(Delayed Data from NSDQ)
$2.29 USD
+0.02 (0.66%)
Updated Apr 26, 2024 03:57 PM ET
After-Market: $2.30 +0.02 (0.66%) 7:54 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
CHEK 2.29 +0.02(0.66%)
Will CHEK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CHEK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CHEK
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
CHEK: What are Zacks experts saying now?
Zacks Private Portfolio Services
CheckCap Ltd. (CHEK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
The Zacks Analyst Blog Highlights ShockWave Medical, CheckCap and Biosig Technologies
3 Medical Instruments Stocks With Potential to Outperform
Other News for CHEK
Check-Cap Ltd. Calls for Shareholder Vote
Check-Cap Ltd. Approaches Key Merger Vote
Check-Cap, Outset Medical, Vincerx Pharma among healthcare movers
Check-Cap Ltd. Calls Shareholders to Vote on Key Proposals
CHEK, HKIT and GCTS among pre-market losers